<DOC>
	<DOCNO>NCT00825084</DOCNO>
	<brief_summary>This study characterize pharmacokinetics single multiple oral dos Dimebon Japanese healthy subject . This study also evaluate safety tolerability single multiple oral dos Dimebon Japanese healthy subject . The secondary objective study compare pharmacokinetics , safety tolerability single multiple oral dos Dimebon Japanese Western healthy subject .</brief_summary>
	<brief_title>A Phase 1 Study To Evaluate The Pharmacokinetics , Safety , And Tolerability Of Dimebon PF-01913539 In Japanese And Western Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG , clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight within range 50 100 kg . An informed consent document sign date subject legallyacceptable representative . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Japanese subject must four Japanese grandparent born Japan . Asian Polynesian subject Western subject group . Any condition possibly affect drug absorption ( e.g. , gastrectomy , active peptic ulcer within last 3 month ) . History regular alcohol consumption exceed average 7 drinks/week female 14 drinks/week men ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . Subjects , history , smoke 5 cigarette per day . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication . 12lead ECG demonstrate QTc &gt; 450 msec screening . If QTc exceed 450 msec , ECG may repeat two time average three QTc value use determine subject 's eligibility . Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method nonhormonal contraception outline protocol least 14 day prior first dose study medication . Use prescription nonprescription drug , vitamin dietary supplement , within 7 day 5 halflives ( whichever longer ) first dose study medication . Herbal supplement hormonal method contraception ( include oral transdermal contraceptive , injectable progesterone , progestin subdermal implant , progesteronereleasing IUDs , postcoital contraceptive method ) hormone replacement therapy must discontinue 28 day prior first dose study medication . DepoProvera® must discontinue least 6 month prior first dose study medication . As exception , acetaminophen/paracetamol may use dos ≤ 2 grams/day . Limited use nonprescription medication believe affect subject safety overall result study may permit casebycase basis follow approval sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Dimebon , Japanese Western population , pharmacokinetics</keyword>
</DOC>